Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galderma S.A.
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
The new public offering will fund the US pivotal trial of the company’s VenoValve device to treat chronic deep venous insufficiency in the legs.
A panel discussed opportunities and challenges in POC testing beyond the pandemic, including the consumer-centric health care environment and continued innovation.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
- OTC, Consumer
- Other Names / Subsidiaries
- CollaGenex Pharmaceuticals, Inc., Nestle S.A.
- Nestle Skin Health S.A.
- Spirig Pharma AG
- Q-Med AB